Effective Inhibition of Xenografts of Hepatocellular Carcinoma (HepG2) by Rapamycin and Bevacizumab in an Intrahepatic Model
Open Access
- 28 March 2009
- journal article
- research article
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 11 (5) , 334-342
Abstract
Purpose Hepatocellular carcinoma (HCC) displays a characteristic hypervascularity and depends on angiogenesis for tumor growth, which thus provides a potential target for therapeutic approaches to HCC. In this study, through the use of combined micro-positron emission tomography (PET)/computed tomography (CT), we investigate if such a combined targeting of vascular endothelial growth factor (VEGF) activity and expression might retard HCC growth in an orthotopic intrahepatic xenograft model. Procedures Xenograft models were created by intraportal vein injection of HepG2 cell suspensions in severe combined immunodeficient mice. The mice were then treated with (1) rapamycin (RAPA), a mammalian target of rapamycin pathway inhibitor; (2) bevazicumab (BEV), a VEGF monoclonal antibody; and (3) a RAPA/BEV combination. Results Assessment of HCC progression using CT with Omnipaque and PET with 2-deoxy-2-(F-18)-fluoro-d-glucose showed that mice treated with RAPA/BEV had the lowest standardized uptake values (SUVs). At week 2, mice treated with RAPA/BEV, RAPA, and BEV all showed a marked decrease in the SUVmax readings with the greatest drop being observed in the RAPA/BEV group (1.33 + 0.26, 1.81 + 0.2, 2.05 + 0.4 vs. vehicle control 2.11 + 0.53). Conclusions Our results, supported by micro-PET/CT, suggest that RAPA/BEV represents a potential novel antiangiogenic therapy for the treatment of HCC.Keywords
This publication has 40 references indexed in Scilit:
- The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A reviewEuropean Journal of Cancer, 2006
- Angiogenesis and antiangiogenic therapy in hepatocellular carcinomaCancer Letters, 2006
- Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal CancerJournal of Clinical Oncology, 2005
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Systemic therapy for advanced hepatocellular carcinoma: a reviewEuropean Journal of Cancer, 2004
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Resection prior to liver transplantation for hepatocellular carcinoma: A strategy of optimizing the role of resection and transplantation in cirrhotic patients with preserved liver functionLiver Transplantation, 2004
- Orthotopic models of cancer for preclinical drug evaluationEuropean Journal of Cancer, 2004
- mTOR Controls Cell Cycle Progression through Its Cell Growth Effectors S6K1 and 4E-BP1/Eukaryotic Translation Initiation Factor 4EMolecular and Cellular Biology, 2004
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002